Cytokine profile in patients with myocardial infarction aged 80 years and older
https://doi.org/10.15829/1728-8800-2025-4553
EDN: NMKHUS
Abstract
Aim. Using a bioresource collection, to study the expression of cytokines, chemokines, and growth factors in patients with myocardial infarction (MI) aged 80 years and older and to establish their relationship with unfavorable outcomes.
Material and methods. This retrospective study included 59 patients aged 80 years and older with acute coronary syndrome (ACS). Clinical and demographic data, laboratory parameters, and biomarker dynamics at hospital admission and after 7 days were analyzed. Thirty-day outcomes were assessed. Patients were divided into groups based on outcomes as follows: group 1 (n=11) — patients who died within 30 days after ACS; group 2 (n=48) — the remaining patients.
Results. Follow-up in the overall group revealed a significant decrease in serum levels of interleukin (IL)-6, IL-8, and granulocyte colony-stimulating factor at day 7 after ACS, while eotaxin levels, conversely, increased. Associations between proinflammatory cytokines and clinical risk stratification scores were revealed. In the fatal group, higher levels of IL-10, IL-15, tumor necrosis factor-alpha, monocyte chemotactic protein 1, granulocyte colony-stimulating factor, macrophage colony-stimulating factor, and N-terminal pro-brain natriuretic peptide (NTproBNP) were noted at day 7 after ACS. The combination of NTproBNP >1000 pg/ml and IL-15 >25 pg/ml on day 7 has the highest prognostic value for predicting patient mortality within 30 days after ACS, with a sensitivity of 83,3% and a specificity of 90,6% (AUC=0,87).
Conclusion. Using a bioresource collection and multiplex technology, the expression of cytokines, chemokines, and growth factors was studied in patients over 80 years of age with myocardial infarction. A model for predicting unfavorable outcomes in patients with myocardial infarction was developed.
Keywords
acute coronary syndrome,
myocardial infarction,
elderly patients,
old age,
cytokines,
chemokines,
growth factors,
bioresource collection
Supporting agencies: The study was conducted within the Research Project № 122020300043-1 of the Cardiology Research Institute of the Tomsk National Research Medical Center
About the Authors
A. M. Gusakova
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya St., 111a, Tomsk, 634012
E. S. Kravchenko
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya St., 111a, Tomsk, 634012
A. G. Syrkina
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya St., 111a, Tomsk, 634012
O. N. Ogurkova
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya St., 111a, Tomsk, 634012
T. E. Suslova
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya St., 111a, Tomsk, 634012
V. V. Ryabov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Kievskaya St., 111a, Tomsk, 634012
References
1. Ryabov VV, Vyshlov EV, Alekseeva YV, et al. Fundamental and clinical problems of acute myocardial infarction. Tomsk: Cardiology Research Institute, 2021. р. 170. (In Russ.) ISBN: 9785604274590.
2. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149(8):e347-e913. doi:10.1161/CIR.0000000000001209.
3. Lawless M, Damluji A, Dirjayanto VJ, et al. Differences in treatment and clinical outcomes in patients aged ≥75 years compared with those aged ≤74 years following acute coronary syndromes: a prospective multicentre study. Open Heart 2023;10:e002418. doi:10.1136/openhrt-2023-002418.
4. Samorodskaya IV, Chernyavskaya TK, Kakorina EP, et al. Ischemic heart disease: medical certificate of cause of death analysis. Russian Journal of Cardiology. 2022;27(1):4637. (In Russ.) doi:10.15829/1560-4071-2022-4637.
5. Sinclair H, Batty JA, Qiu W, Kunadian V. Engaging older patients in cardiovascular research: observational analysis of the ICON-1 study. Open Heart. 2016;3(2):e000436. doi:10.1136/openhrt-2016-000436.
6. Butuhanova IS, Sodnomova LB. Problems of diagnosis and treatment of acute coronary syndrome in elderly and senile age. Sovremennye problemy nauki i obrazovanija. 2016;(3):12-9. (In Russ.)
7. Veerasamy M, Edwards R, Ford G, et al. Acute coronary syndrome among older patients: a review. Cardiol Rev. 2015;23(1):26-32. doi:10.1097/CRD.0000000000000016.
8. Mehta SR, Wood DA, Storey RF, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. NEJM. 2019;381: 1411-21. doi:10.1056/nejmoa1907775.
9. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. Acute Cardiovasc Care. 2024;13(1):55-161. doi:10.1093/ehjacc/zuad107.
10. Biscaglia S, Guiducci V, Escaned J, et al. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. N Engl J Med. 2023;389(10):889-98. doi:10.1056/NEJMoa2300468.
11. Duplyakova PD, Pavlova TV, Duplyakov DV. Analysis of outcomes in patients with ST-segment elevation myocardial infarction aged 90 years and older: a single center experience. Russian Journal of Cardiology. 2023;28(4S):5706. (In Russ.) doi:10.15829/1560-4071-2023-5706.
12. Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 2005; 66(2):265-275. doi:10.1016/j.cardiores.2004.12.026.
13. Russian Society of Cardiology. 2020 Clinical practice guidelines for acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) doi:10.15829/1560-4071-2020-4103.
14. Stoicescu L, Cri¸san D, Morgovan C, et al. Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach. Int J Mol Sci. 2024;25(2):794. doi:10.3390/ijms25020794.
15. Matter MA, Paneni F, Libby P, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024;45(2):89-103. doi:10.1093/eurheartj/ehad486.
16. Ryabov V, Samoilova Y, Gombozhapova A, et al. Associations Between Plasma Levels of NLRP3 Protein, Interleukin-1 Beta and Features of Acute ST-Elevation Myocardial Infarction. J Pers Med. 2024;14(11):1103. doi:10.3390/jpm14111103.
17. Nurmohamed NS, Kraaijenhof JM, Mayr M, et al. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur Heart J. 2023;44(18):1594-607. doi:10.1093/eurheartj/ehad161.
18. Eggers KM, Lindhagen L, Baron T, et al. Sex-differences in circulating biomarkers during acute myocardial infarction: An analysis from the SWEDEHEART registry. PLoS ONE. 2021;16(4): e0249830. doi:10.1371/journal.pone.0249830.
19. Gusakova AM, Kravchenko ES, Suslova TE, et al. Biobanks in cardiovascular disease research. Cardiovascular Therapy and Prevention. 2024;23(11):4170. (In Russ.) doi:10.15829/1728-8800-2024-4170.
20. Sushentseva NN, Popov OS, Apalko SV, et al. Biobank as a source of samples for determination of concentration reference ranges for cytokines, chemokines and growth factors circulating in the blood. Cardiovascular Therapy and Prevention. 2022;21(11):3396. (In Russ.) doi:10.15829/1728-8800-2022-3396.
21. Arsentieva NA, Liubimova NE, Batsunov OK, et al. Predictive value of specific cytokines for lethal COVID-19 outcome. Rus J Infect Immun. 2022;12(5):859-68. doi:10.15789/2220-7619-PVO-2043.
22. Zhang H, Dhalla NS. The Role of Pro-Inflammatory cytokines in the pathogenesis of cardiovascular disease. Int J Mol Sci. 2024; 25(2):1082. doi:10.3390/ijms25021082.
23. Lobo-Silva D, Carriche GM, Castro AG, et al. Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflamm. 2016;13(1):297. doi:10.1186/s12974-016-0763-8.
24. Rajappa M, Sen SK, Sharma A. Role of pro-/anti-inflammatory cytokines and their correlation with established risk factors in South Indians with coronary artery disease. Angiology. 2009; 60(4):419-26. doi:10.1177/0003319708321101.
25. Gokkusu C, Aydin M, Ozkok E, et al. Influences of genetic variants in interleukin-15 gene and serum interleukin-15 levels on coronary heart disease. Cytokine. 2010;49(1):58-63. doi:10.1016/j.cyto.2009.09.004.
26. Smykiewicz P, Segiet A, Keag M, et al. Proinflammatory cytokines and ageing of the cardiovascular-renal system. Mech Ageing Dev. 2018;175:35-45. doi:10.1016/j.mad.2018.07.006.
27. Dorobanţu M, Câlmâc L, Bogdan A, et al. Particularities in coronary revascularization in elderly patients presenting with ST segment elevation acute myocardial infarction (STEMI). Cor Vasa. 2014; 56(4): e342-7. doi:10.1016/j.crvasa.2014.06.005.
28. Hamzic-Mehmedbasic A. Inflammatory Cytokines as risk factors for mortality after acute cardiac events. Med Arch. 2016;70(4): 252-5. doi:10.5455/medarh.2016.70.252-255.
29. Kravchenko ES, Suslova TE, Kologrivova IV, et al. Eotaxin and cardio-ankle vascular index in patients with high and very high cardiovascular risk. Medical Immunology. 2023;25(4):971-6. (In Russ.) doi:10.15789/1563-0625-EAC-2768.
30. Căruntu F, Bordejevic DA, Buz B, et al. Independent predictors of in-hospital and 1-year mortality rates in octogenarians with acute myocardial infarction. Rev Cardiovasc Med. 2021;22(2):489-97. doi:10.31083/j.rcm2202056.
31. Shalnova SA, Drapkina OM, Kutsenko VA, et al. Myocardial infarction in the population of some Russian regions and its prognostic value. Russian Journal of Cardiology. 2022;27(6):4952. (In Russ.) doi:10.15829/1560-4071-2022-4952.
32. Barbarash OL, Usoltseva EN, Shafranskaya KS, et al. N-terminal brain natriuretic propeptide as a marker of multifocal atherosclerosis in patients with ST segment elevation myocardial infarction. Russian Journal of Cardiology. 2012;(3):12-8. (In Russ.) EDN: OYIKLH.
33. Ruda MY, Shakhnovich RM, Shreyder EV. Prognostic influence of inflammation markers and NT-proBNP indifferent ACS management strategies. Cardiology bulletin. 2008;2(3):44-52. (In Russ.)
34. Weber M, Bazzino O, Navarro Estrada JL, et al. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J Am Coll Cardiol. 2008;51(12):1188-95. doi:10.1016/j.jacc.2007.11.054.
35. Abo-Aly M, Shokri E, Chelvarajan L, et al. Prognostic significance of activated monocytes in patients with ST-elevation myocardial infarction. Int J Mol Sci. 2023;24(14):11342. doi:10.3390/ijms241411342.
Supplementary files
What is already known about the subject?
- Bioresource collections, combined with clinical, demographic, and paraclinical data, are an effective tool for studying risk factors and identifying the pathophysiological mechanisms underlying unfavorable outcomes.
- Patients over 80 years of age represent a high-risk group for developing complications after acute coronary syndrome (ACS). Identifying elderly patients with a secretory phenotype associated with adverse cardiovascular events after ACS is relevant.
What might this study add?
- Using a bioresource collection, the expression of cytokines, chemokines, and growth factors in patients over 80 years of age with ACS was studied, and their relationship with unfavorable outcomes was established.
- The obtained results make it possible to identify priority groups of patients differing in the level of biomarkers in the post-infarction period, and to further develop approaches aimed at reducing the risk of complications and unfavorable outcomes in elderly patients with ACS.
Review
For citations:
Gusakova A.M., Kravchenko E.S., Syrkina A.G., Ogurkova O.N., Suslova T.E., Ryabov V.V. Cytokine profile in patients with myocardial infarction aged 80 years and older. Cardiovascular Therapy and Prevention. 2025;24(11):4553. (In Russ.) https://doi.org/10.15829/1728-8800-2025-4553. EDN: NMKHUS
Views:
112
JATS XML
Email this article 
